Multiple sclerosis patients whose blood tests reveal elevated NfL, a biomarker of nerve damage, could see worsening disability one to two years later, according to a new study spearheaded by researchers at UC San Francisco.
Scoop: Novartis axes mid-stage depression trial of ketamine-like injection
Novartis has scrapped a Phase II clinical trial of an investigational treatment for major depressive disorder related to suicidal ideation, the Swiss Big Pharma confirmed
October 10, 2023